tiprankstipranks
HIMS Earnings: Hims & Hers Skyrockets on Q4 Beat
Market News

HIMS Earnings: Hims & Hers Skyrockets on Q4 Beat

Story Highlights

Hims & Hers delivered robust numbers for the fourth quarter. The company remains optimistic about its future due to healthy demand for its offerings.

Hims & Hers (NYSE:HIMS) shares surged nearly 20% in the early session today after the telehealth platform’s fourth-quarter revenue jumped by 47.5% year-over-year to $246.6 million. Further, EPS of $0.01 exceeded estimates by $0.03.

Don't Miss our Black Friday Offers:

For the full year, revenue increased by 65% to $872 million. In Q4, the company’s subscriber base ballooned by 48% year-over-year to 1.5 million, and net orders rose by 24% to 2.3 million. However, its monthly online revenue per average subscriber moderated to $53 from $55 in the year-ago period.

Moreover, HIMS experienced robust double-digit growth across its Online and Wholesale verticals. This increase was accompanied by a robust 400 basis point expansion in the company’s gross margin.

For Fiscal Year 2024, HIMS expects revenue of $1.17 billion to $1.20 billion. Adjusted EBITDA for the year is anticipated in the range of $100 million to $120 million. For Q1, the company foresees revenue of $267 million to $272 million. Adjusted EBITDA for the quarter is seen landing between $22 million and $27 million. Notably, with demand for its personalized care solutions remaining buoyant, the company remains well on track to achieve its financial targets for 2025.

Is Hims & Hers a Good Stock to Buy?

Today’s price gains come on top of a nearly 50% rally in the company’s share price over the past six months. Overall, the Street has a Moderate Buy consensus rating on Hims & Hers alongside an average price target of $11.07. However, analysts’ views on the stock could change following its Q4 print.

Read full Disclosure

Related Articles
TipRanks Auto-Generated NewsdeskHims & Hers Health Expands Board with New Appointment
TheFlyFDA tirzepatide status report ‘moderately positive’ for Hims & Hers, says Citi
TheFlyHims & Hers jumps as status report says patients unable to obtain branded GLP-1s
Go Ad-Free with Our App